Uniqure NV:
* Findings further support expanding eligibility of AAV5 gene therapies to nearly all patients with hemophilia B Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)
July 11th, 2017 | 06:39 AM market healthcare 181
Uniqure NV:
* Findings further support expanding eligibility of AAV5 gene therapies to nearly all patients with hemophilia B Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)